-

Bristol Myers Squibb to Present at J.P. Morgan’s 42nd Annual Healthcare Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 42nd Annual Healthcare Conference in San Francisco, California, on Monday, January 8, 2024. Christopher Boerner, Ph.D., chief executive officer, will make a formal presentation and answer questions about the company at 7:30 a.m. PST/10:30 a.m. EST.

The event will be webcast simultaneously at http://investor.bms.com with materials related to the presentation available at the start of the live webcast. A replay and archived edition of the presentation will be available following the event.

About Bristol Myers Squibb Company

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

Contacts

For more information, contact:

Media:
media@bms.com

Investors:
investor.relations@bms.com

Industry:

Bristol Myers Squibb

NYSE:BMY
Release Summary
Bristol Myers Squibb to Present at J.P. Morgan's 42nd Annual Healthcare Conference
Release Versions
English

Contacts

For more information, contact:

Media:
media@bms.com

Investors:
investor.relations@bms.com

More News From Bristol Myers Squibb

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)--Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival.......

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

PRINCETON, N.J.--(BUSINESS WIRE)--US FDA Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos to Treat Adolescents with oHCM...

Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

PRINCETON, N.J.--(BUSINESS WIRE)--BMS Announces Opdivo (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma...
Back to Newsroom